161tb-dota-lm3
Small moleculeexperimentalImaging agent
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 31, 2022 (NCT05359146)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Unspecified targetRadiopharmaceutical
radiopharmaceutical
Chemistry & pharmacology
- Imaging
- 161-terbium
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05359146 | Early Phase 1 (Phase 1) | Dec 31, 2022 | Swiss National Science Foundation, University of Basel |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Swiss National Science Foundation | Government | 1 | 0 | 1 | 2022 |
| University of Basel | Academic/Hospital | 1 | 1 | 1 | 2022 |
2 organizations
Page 1 / 1